Janux Therapeutics (JANX) Competitors $24.05 -1.07 (-4.26%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$24.13 +0.08 (+0.33%) As of 09/12/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JANX vs. TGTX, MRUS, CRSP, PTCT, KRYS, PCVX, ACAD, ACLX, ADMA, and ARWRShould you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include TG Therapeutics (TGTX), Merus (MRUS), CRISPR Therapeutics (CRSP), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), ADMA Biologics (ADMA), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Janux Therapeutics vs. Its Competitors TG Therapeutics Merus CRISPR Therapeutics PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Arrowhead Pharmaceuticals Janux Therapeutics (NASDAQ:JANX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings. Which has higher earnings and valuation, JANX or TGTX? TG Therapeutics has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$10.59M136.47-$68.99M-$1.80-13.36TG Therapeutics$454.07M11.24$23.38M$0.3786.92 Is JANX or TGTX more profitable? TG Therapeutics has a net margin of 13.31% compared to Janux Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 26.05% beat Janux Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Janux TherapeuticsN/A -11.48% -11.01% TG Therapeutics 13.31%26.05%9.58% Do insiders and institutionals hold more shares of JANX or TGTX? 75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 8.1% of Janux Therapeutics shares are owned by company insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, JANX or TGTX? Janux Therapeutics has a beta of 2.84, suggesting that its share price is 184% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Does the media refer more to JANX or TGTX? In the previous week, Janux Therapeutics had 7 more articles in the media than TG Therapeutics. MarketBeat recorded 16 mentions for Janux Therapeutics and 9 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.04 beat Janux Therapeutics' score of 0.79 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate JANX or TGTX? Janux Therapeutics presently has a consensus price target of $80.92, suggesting a potential upside of 236.45%. TG Therapeutics has a consensus price target of $46.25, suggesting a potential upside of 43.81%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Janux Therapeutics is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.07TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryTG Therapeutics beats Janux Therapeutics on 9 of the 17 factors compared between the two stocks. Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition Export to ExcelMetricJanux TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.51B$3.20B$5.87B$10.13BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-13.3621.1774.5225.93Price / Sales136.47435.97518.91181.69Price / CashN/A46.6837.5660.44Price / Book1.239.6112.166.29Net Income-$68.99M-$53.29M$3.28B$270.77M7 Day Performance0.29%0.12%0.78%3.84%1 Month Performance-3.65%5.60%4.87%4.85%1 Year Performance-51.91%10.47%60.72%26.00% Janux Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics2.5021 of 5 stars$24.05-4.3%$80.92+236.5%-48.3%$1.51B$10.59M-13.3630News CoveragePositive NewsAnalyst ForecastTGTXTG Therapeutics4.1392 of 5 stars$32.38+0.5%$46.25+42.8%+38.7%$5.11B$329M87.51290Positive NewsInsider TradeMRUSMerus3.0637 of 5 stars$67.19-0.4%$88.75+32.1%+41.6%$5.10B$36.13M-12.2237Positive NewsCRSPCRISPR Therapeutics3.4272 of 5 stars$54.10-1.4%$71.60+32.3%+22.6%$4.99B$37.31M-9.96460News CoveragePTCTPTC Therapeutics3.6676 of 5 stars$56.95-0.5%$69.00+21.2%+86.8%$4.55B$806.78M8.171,410News CoveragePositive NewsInsider TradeKRYSKrystal Biotech4.9297 of 5 stars$145.20-3.4%$210.38+44.9%-26.6%$4.35B$290.52M29.51210Positive NewsPCVXVaxcyte2.2466 of 5 stars$32.41-1.8%$130.00+301.1%-71.8%$4.29BN/A-7.89160News CoveragePositive NewsAnalyst ForecastACADACADIA Pharmaceuticals4.3796 of 5 stars$25.39+0.5%$28.88+13.7%+48.0%$4.26B$957.80M19.09510News CoverageAnalyst ForecastACLXArcellx2.2409 of 5 stars$71.11-2.1%$114.31+60.7%+1.9%$4.03B$107.94M-20.7980Positive NewsADMAADMA Biologics3.7102 of 5 stars$16.42-2.7%$27.67+68.5%-8.7%$4.03B$426.45M19.09530Positive NewsARWRArrowhead Pharmaceuticals4.1438 of 5 stars$27.17-6.6%$43.14+58.8%+46.9%$4.02B$3.55M-21.23400Analyst Revision Related Companies and Tools Related Companies TGTX Competitors MRUS Competitors CRSP Competitors PTCT Competitors KRYS Competitors PCVX Competitors ACAD Competitors ACLX Competitors ADMA Competitors ARWR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JANX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
